-
Media Release
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
-
Media Release
Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
-
Media Release
Novartis drug Afinitor® is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
-
Media Release
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
-
Media Release
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
-
Media Release
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
-
Media Release
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
-
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media Release
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
-
Media Release
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
-
Media Release
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma